Spencer, K. R., Punekar, S. R., Grierson, P., Mitchell, J., Lin, Y., Castria, T. B. D., Zhen, D. B., Vu, P., Morelli, M. P., Kundranda, M. N., Dorigo, O., Maloney, D. G., Ward, J., Eng, C., Maus, M. V., Simeone, D. M., Welch, J. S., Molina, J. R., Go, W. Y., Hecht, J. R. (2025). EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps788